| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| D J Nutt, J M Peill, B Weiss, K Godfrey, R L Carhart-Harris, D Erritzo. Psilocybin and Other Classic Psychedelics in Depression. Current topics in behavioral neurosciences. 2023-11-13. PMID:37955822. |
psilocybin and other classic psychedelics in depression. |
2023-11-13 |
2023-11-20 |
Not clear |
| D J Nutt, J M Peill, B Weiss, K Godfrey, R L Carhart-Harris, D Erritzo. Psilocybin and Other Classic Psychedelics in Depression. Current topics in behavioral neurosciences. 2023-11-13. PMID:37955822. |
psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders including the treatment of depression. |
2023-11-13 |
2023-11-20 |
Not clear |
| Uriel Heresco-Levy, Bernard Lere. Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders. Molecular psychiatry. 2023-11-09. PMID:37945694. |
we propose to initially focus research on the acute concurrent administration of psilocybin and dsr or dcs in depression. |
2023-11-09 |
2023-11-20 |
Not clear |
| Zofia Kozak, Matthew W Johnson, Scott T Aaronso. Assessing potential of psilocybin for depressive disorders. Expert opinion on investigational drugs. 2023-11-02. PMID:37869790. |
several clinical trials have shown psilocybin to have efficacy in reducing symptoms of depression. |
2023-11-02 |
2023-11-08 |
Not clear |
| Arya Rahbarnia, Zhaoxia Li, Paul J Fletche. Effects of psilocybin, the 5-HT Psychopharmacology. 2023-10-19. PMID:37855864. |
effects of psilocybin, the 5-ht neuropsychiatric disorders such as depression are characterized in part by attention deficits. |
2023-10-19 |
2023-11-08 |
Not clear |
| Sipan Haikazian, David C J Chen-Li, Danica E Johnson, Farhan Fancy, Anastasia Levinta, M Ishrat Husain, Rodrigo B Mansur, Roger S McIntyre, Joshua D Rosenbla. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry research. vol 329. 2023-10-16. PMID:37844352. |
systematic searches were conducted to search for randomized clinical trials and open-label trials that evaluated depression symptoms after psilocybin therapy. |
2023-10-16 |
2023-11-08 |
Not clear |
| Sipan Haikazian, David C J Chen-Li, Danica E Johnson, Farhan Fancy, Anastasia Levinta, M Ishrat Husain, Rodrigo B Mansur, Roger S McIntyre, Joshua D Rosenbla. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry research. vol 329. 2023-10-16. PMID:37844352. |
the primary outcome was the standardized mean difference (smd) in depression severity, determined by calculating the change in depression ratings from baseline to the primary endpoint in the psilocybin arm versus the control arm. |
2023-10-16 |
2023-11-08 |
Not clear |
| Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek, Andrzej Pil. Potential use of psilocybin drugs in the treatment of depression. Expert opinion on emerging drugs. 2023-10-11. PMID:37817501. |
potential use of psilocybin drugs in the treatment of depression. |
2023-10-11 |
2023-10-15 |
Not clear |
| Kwonmok Ko, Ben Carter, Anthony J Cleare, James J Rucke. Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis. Neuropsychiatric disease and treatment. vol 19. 2023-10-11. PMID:37818448. |
determining predictors of their intensity is, therefore, potentially beneficial in targeting psilocybin therapy for depression. |
2023-10-11 |
2023-10-15 |
Not clear |
| Haniya J Halim, Bradley G Burk, Rachel E Fargason, Badari Biru. Manic episode following psilocybin use in a man with bipolar II disorder: a case report. Frontiers in psychiatry. vol 14. 2023-10-09. PMID:37810598. |
psilocybin is a psychedelic drug that has recently garnered increased interest as an effective treatment modality for treatment-resistant depression, depression associated with terminal conditions, certain substance use disorders, and obsessive-compulsive disorder. |
2023-10-09 |
2023-10-15 |
Not clear |
| Haniya J Halim, Bradley G Burk, Rachel E Fargason, Badari Biru. Manic episode following psilocybin use in a man with bipolar II disorder: a case report. Frontiers in psychiatry. vol 14. 2023-10-09. PMID:37810598. |
given the incidence of depression in those with bipolar disorder, impulsivity, and a tendency to abuse substances associated with the illness, further research is needed into the risks of psilocybin and other psychedelic use in those with bipolar disorder. |
2023-10-09 |
2023-10-15 |
Not clear |
| Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, David Menkes, William Evans, Nicholas Hoeh, Frederick Sundram, Lisa Reynolds, Rhys Ponton, Alana Cavadino, Todd Smith, Partha Roop, Nathan Allen, Binu Abeysinghe, Darren Svirskis, Anna Forsyth, Mahima Bansal, Suresh Muthukumaraswam. An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1). Pilot and feasibility studies. vol 9. issue 1. 2023-10-05. PMID:37798662. |
in light of problems with the tolerability and efficacy of available treatments [2], a global trend is emerging for patients to self-treat depression with microdoses of psychedelic drugs such as lysergic acid diethylamide (lsd) and psilocybin [3]. |
2023-10-05 |
2023-10-07 |
human |
| Thomas J Kelly, Emma M Bonniwell, Lianwei Mu, Xiaojie Liu, Ying Hu, Vladislav Friedman, Hao Yu, Wantang Su, John D McCorvy, Qing-Song Li. Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023-09-26. PMID:37752222. |
psychedelics such as psilocybin show great promise for the treatment of depression and ptsd, but their long duration of action poses practical limitations for patient access. |
2023-09-26 |
2023-10-07 |
human |
| Amir Garakani, Jeanne L Alexander, Calvin R Sumner, Janet H Pine, Lawrence S Gross, Charles L Raison, Scott T Aaronson, David A Baro. Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. Journal of psychiatric practice. vol 29. issue 5. 2023-09-07. PMID:37678363. |
while discussing psychedelics in general, the focus of this paper is on psilocybin and its mechanism, how it exerts a psychedelic effect, dosing, and a review of the treatment studies of psilocybin, which were primarily for treatment-resistant depression and cancer-related anxiety. |
2023-09-07 |
2023-10-07 |
Not clear |
| Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet, Dean Calhou. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits. Journal of applied toxicology : JAT. 2023-08-30. PMID:37646119. |
serotonergic psychedelics, such as lysergic acid diethylamide (lsd), psilocybin, dimethyltryptamine (dmt), and 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. |
2023-08-30 |
2023-09-07 |
Not clear |
| Robert F Dougherty, Patrick Clarke, Merve Atli, Joanna Kuc, Danielle Schlosser, Boadie W Dunlop, David J Hellerstein, Scott T Aaronson, Sidney Zisook, Allan H Young, Robin Carhart-Harris, Guy M Goodwin, Gregory A Rysli. Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing. Psychopharmacology. 2023-08-22. PMID:37606733. |
psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing. |
2023-08-22 |
2023-09-07 |
human |
| Robert F Dougherty, Patrick Clarke, Merve Atli, Joanna Kuc, Danielle Schlosser, Boadie W Dunlop, David J Hellerstein, Scott T Aaronson, Sidney Zisook, Allan H Young, Robin Carhart-Harris, Guy M Goodwin, Gregory A Rysli. Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing. Psychopharmacology. 2023-08-22. PMID:37606733. |
a recent randomized double-blind phase-iib study demonstrated the safety and efficacy of comp360, compass pathways' proprietary synthetic formulation of psilocybin, in participants with treatment-resistant depression. |
2023-08-22 |
2023-09-07 |
human |
| Raul Escamilla, María Eva González-Trujano, Jesús M González Mariscal, Jesús Martín Torres-Valencia, Héctor Guzmán-González, José Luis Vega, Anja Loizaga-Velde. A Proposal to Study the Safety and Efficacy of Journal of psychoactive drugs. 2023-08-18. PMID:37594163. |
psilocybin is today a novel and breakthrough therapy for major depression. |
2023-08-18 |
2023-09-07 |
Not clear |
| Marie Crowe, Jenni Manuel, Dave Carlyle, Cameron Lace. Psilocybin-assisted psychotherapy for treatment-resistant depression: Which psychotherapy? International journal of mental health nursing. 2023-08-17. PMID:37589380. |
the paper will examine whether three one-to-one psychotherapies identified as effective in the treatment of treatment-resistant depression are compatible with the psilocybin experience. |
2023-08-17 |
2023-09-07 |
Not clear |
| Ayana Jorda. Emerging Perspectives in Addiction Psychiatry. The Journal of clinical psychiatry. vol 84. issue 4. 2023-08-09. PMID:37555675. |
already, some evidence supports the use of psilocybin in alleviating symptoms of depression and anxiety; psychedelic compounds also have potential as alcohol use disorder treatments and may help reduce symptoms tied to opioid withdrawal. |
2023-08-09 |
2023-08-16 |
Not clear |